Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + remifentanil + midazolam
- Development stage
- Unknown
- Lead developer
- China-Japan Friendship Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Propofol + remifentanil + midazolam is a multi-agent anesthetic regimen utilized in total intravenous anesthesia (TIVA). This combination leverages the distinct pharmacological profiles of three small-molecule agents to achieve a balanced state of general anesthesia: **propofol**, a fast-acting hypnotic that acts as a positive allosteric modulator of the GABA-A receptor; **remifentanil**, an ultra-short-acting synthetic mu-opioid receptor agonist providing potent analgesia; and **midazolam**, a benzodiazepine that also modulates GABA-A receptors to provide supplemental sedation and anxiolysis. This specific regimen is frequently studied in clinical settings, such as at the China-Japan Friendship Hospital, to optimize anesthesia depth monitoring (e.g., via the Bispectral Index) and improve recovery quality in patients undergoing major surgical procedures like total knee replacement.
- Other names
- Propofol-Remifentanil-Midazolam TIVA regimen
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on propofol + remifentanil + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + remifentanil + midazolam.